SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (783)2/5/2004 2:53:56 AM
From: Icebrg  Read Replies (2) of 2240
 
Genmab - 2003. From today's report.

Highlights
During 2003, Genmab had a large number of accomplishments including:

HuMax-CD4
* Initiated two Phase II clinical trials to treat cutaneous T-cell lymphoma (CTCL).
* Presented positive preliminary results of two ongoing Phase II CTCL studies at American Society of Hematology (ASH) meeting in December 2003.
* Expanded Phase II CTCL trials to include more patients and higher doses.
* Discontinued plans to develop HuMax-CD4 for the treatment of psoriasis.

HuMax-IL15/Amgen Alliance
* Amgen (NASDAQ: AMGN - news) exercised commercialisation option for HuMax-IL15 and IL-15 receptor programs earlier than expected and Genmab received USD 10 million milestone payment.
* Amgen expanded agreement to include a new antibody on an additional disease target.
* Achieved second Amgen milestone by delivering an antibody targeting the IL-15 receptor and received USD 500,000 milestone payment.
* Amgen assumed responsibility for further development costs.

HuMax-EGFr
* HuMax-EGFr shown to induce regression of certain established tumors in animal disease models.
* Initiated Phase I/II clinical trial to treat head and neck cancer.

HuMax-CD20
* In both laboratory studies and animal disease models, HuMax-CD20 appeared to be more effective at killing tumour cells than rituximab, a leading antibody product currently on the market.
* Presented HuMax-CD20 data demonstrating unique binding properties at ASH.
* Filed US Investigational New Drug and UK Clinical Trial Application to initiate Phase I/II clinical trials to treat non-Hodgkin's lymphoma.

HuMax-HepC
* Expanded product pipeline with HuMax-HepC to treat Hepatitis C.

Roche Alliance
* Reached first and second milestones under Roche agreement by establishing proof of concept for two different human antibodies.

ACE BioSciences Collaboration
* Announced new fungal infection program with ACE BioSciences.

Sanquin Collaboration
* Established a collaboration with Sanquin Blood Supply Foundation with intent to improve treatment for hemophilia patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News